JP2015502958A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502958A5
JP2015502958A5 JP2014546103A JP2014546103A JP2015502958A5 JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5 JP 2014546103 A JP2014546103 A JP 2014546103A JP 2014546103 A JP2014546103 A JP 2014546103A JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5
Authority
JP
Japan
Prior art keywords
subject
effective amount
therapeutically effective
pathway inhibitor
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014546103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/068351 external-priority patent/WO2013086260A2/fr
Publication of JP2015502958A publication Critical patent/JP2015502958A/ja
Publication of JP2015502958A5 publication Critical patent/JP2015502958A5/ja
Pending legal-status Critical Current

Links

JP2014546103A 2011-12-09 2012-12-07 がんの処置のための併用療法 Pending JP2015502958A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161568844P 2011-12-09 2011-12-09
US61/568,844 2011-12-09
US201261698030P 2012-09-07 2012-09-07
US61/698,030 2012-09-07
PCT/US2012/068351 WO2013086260A2 (fr) 2011-12-09 2012-12-07 Thérapie d'association pour le traitement du cancer

Publications (2)

Publication Number Publication Date
JP2015502958A JP2015502958A (ja) 2015-01-29
JP2015502958A5 true JP2015502958A5 (fr) 2016-02-04

Family

ID=48575059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546103A Pending JP2015502958A (ja) 2011-12-09 2012-12-07 がんの処置のための併用療法

Country Status (4)

Country Link
US (1) US20150132301A1 (fr)
EP (1) EP2788378A4 (fr)
JP (1) JP2015502958A (fr)
WO (1) WO2013086260A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3281640A1 (fr) 2011-06-17 2018-02-14 President and Fellows of Harvard College Frizzled 2 en tant que cible pour des anticorps thérapeutiques dans le traitement du cancer
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
WO2015009851A1 (fr) * 2013-07-16 2015-01-22 Icahn School Of Medicine At Mount Sinai Procédés permettant de traiter le cancer chez des sujets atteints d'un dysfonctionnement métabolique
WO2015013579A1 (fr) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions permettant d'améliorer l'avantage thérapeutique du bisantrène
EP3077546A4 (fr) * 2013-12-02 2017-04-26 Oncomed Pharmaceuticals, Inc. Identification de biomarqueurs predictifs associes a des inhibiteurs de la voie wnt
WO2015145388A2 (fr) * 2014-03-27 2015-10-01 Novartis Ag Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
EP2975047A1 (fr) * 2014-07-18 2016-01-20 Université de Lausanne Polypeptides Wnt7a et leur utilisation
US20180244783A1 (en) * 2015-08-31 2018-08-30 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3596463A4 (fr) * 2017-03-16 2021-03-03 The Board of Trustees of the Leland Stanford Junior University Méthodes diagnostiques et thérapeutiques pour des cancers kras-positifs
CN107441045B (zh) * 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
CN117677398A (zh) * 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
US20230383360A1 (en) * 2021-12-16 2023-11-30 D2G Oncology, Inc. Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142481A0 (en) * 2001-04-05 2002-03-10 Yissum Res Dev Co A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof
JP5133071B2 (ja) * 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
KR20090071603A (ko) * 2006-09-19 2009-07-01 노파르티스 아게 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
JP5363350B2 (ja) * 2007-03-19 2013-12-11 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
US20090082328A1 (en) * 2007-05-11 2009-03-26 Bayer Schering Pharma Aktiengesellschaft Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
EP2164850B1 (fr) * 2007-06-12 2016-01-13 Genentech, Inc. Azaindoles n-substitués et procédés d'utilisation
CN101801966A (zh) * 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
CA2924436A1 (fr) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Combinaisons pharmaceutiques de n-3(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide comme inhibiteurs de mek et methodes d'utilisation
CN103479604B (zh) * 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
US20100267626A1 (en) * 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
WO2009064675A1 (fr) * 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Inhibiteurs de la mapk/erk kinase
WO2010037041A2 (fr) * 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
CN103948600A (zh) * 2009-03-11 2014-07-30 阿迪生物科学公司 用于治疗特定癌症的包含rdea119/bay869766的药物组合
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
ES2714875T3 (es) * 2010-03-09 2019-05-30 Dana Farber Cancer Inst Inc Métodos de diagnóstico y tratamiento del cáncer en pacientes que presentan o desarrollan resistencia a una primera terapia del cáncer
CA2794674A1 (fr) * 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Agents de liaison aux recepteurs frizzled et leurs utilisations
US20120231965A1 (en) * 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
MA34948B1 (fr) * 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications

Similar Documents

Publication Publication Date Title
JP2015502958A5 (fr)
IL267609B (en) Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases
HK1243919A1 (zh) 利用tor激酶抑制劑治療癌症
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
EP3019491A4 (fr) Inhibiteurs de kinase pour le traitement d'une maladie
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
WO2015003360A3 (fr) Composés thérapeutiquement actifs et leurs méthodes d'utilisation
EP3065549A4 (fr) Méthodes d'inhibition de la kinase tie2 utiles dans le traitement du cancer
HK1202247A1 (en) Treatment of cancer with tor kinase inhibitors tor
HK1201750A1 (en) Treatment of cancer with tor kinase inhibitors tor
PT3004108T (pt) Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
HK1201753A1 (en) Treatment of cancer with tor kinase inhibitors tor
IL248882A0 (en) Treatment of complications of chronic liver disease with caspase inhibitors
WO2015003355A3 (fr) Composés thérapeutiquement actifs et leurs méthodes d'utilisation
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
HK1198128A1 (en) Use of arctigenin in the preparation of medicament for the treatment of gastrointestinal ulcer diseases
HK1210412A1 (zh) 鹽和糖的混合物在製備用於治療哺乳動物的陰道鬆弛綜合征或陰道乾燥疾病的藥物中的用途
HUP1300025A2 (hu) Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak elõállítására és alkalmazása
TN2014000218A1 (en) Kinase inhibitors